MHMingyao Huang

Mingyao Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mingyao Huang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors

    by Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li

    Glioma is an aggressive brain malignancy characterized by a markedly immunosuppressive microenvironment and limited response to conventional treatments. CD


  • Open Access

    CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies

    by Mingyao Huang, Siyang Wang, Huiyan Huang, Linze Li, Tian Wang

    Gynecological malignancies, including ovarian, cervical, and endometrial cancers, represent a substantial global health burden, contributing significantly to morbidity and mortality among women. Despite advancements in therapeutic strategies, outcomes for many patients remain suboptimal due to challenges such as late-stage detection and resistance to standard treatments. The advent of chimeric antigen receptor (CAR)-engineered natural killer (NK) cells has introduced a cutting-edge immunotherapy option. This review provides an in-depth exploration of the development of CAR-NK cells, emphasizing their sources, design methodologies, and applications in managing gynecological cancers. It also examines current obstacles and outlines innovative strategies to improve the effectiveness and safety of CAR-NK cell-based therapies. Furthermore, we discuss prospective advancements, highlighting the importance of ongoing research and technological innovation to unlock the full potential of CAR-NK cells in the fight against gynecological cancers.


  • Histone lactylation in gastrointestinal cancers: developing immunotherapeutic drugs targeting epigenetics

    by Mingyao Huang

    Gastrointestinal cancers (GICs) remain a major global health burden due to their aggressive nature, therapeutic resistance, and immunosuppressive tumor microenvironment (TME). Histone lactylation, a novel epigenetic modification driven by tumor-derived lactate, has emerged as a key mediator linking metabolic reprogramming to gene expression and immune regulation. In GICs, aberrant lactylation contributes to M2 macrophage polarization, increased PD-L1 expression, and diminished cytotoxic immune cell infiltration, all of which are associated with poor prognosis and resistance to immunotherapy. Targeting histone lactylation-related enzymes-such as p300, SIRT2, and LDHA-or interfering with lactate metabolism offers promising avenues to reshape the TME and enhance responses to immune checkpoint blockade. This review highlights the mechanistic underpinnings and immunological consequences of histone lactylation in GICs and discusses emerging therapeutic strategies that leverage this epigenetic axis to improve cancer immunotherapy outcomes.